May 8, 2026 Adipotide, also known as FTTP (Fat Targeted Pro-apoptotic Peptide), is an experimental peptidomimetic research agent designed to target and eliminate white adipose tissue. Research indicates that Adipotide…
Read more
May 8, 2026 AICAR (Aminoimidazole carboxamide ribonucleotide) is a synthetic analog of adenosine monophosphate (AMP) that serves as a potent metabolic regulator. Research indicates that AICAR is a cell-permeable activator…
Read more
May 8, 2026 AOD9604 (Advanced Obesity Drug) is a synthetic peptide fragment derived from the C-terminal end of human growth hormone (hGH), specifically encompassing amino acids 177-191 with an added…
Read more
May 8, 2026 Retatrutide (also known as LY3437943) is an experimental synthetic peptide that represents the frontier of metabolic research. It is a “triple agonist” (tri-agonist) designed to target three…
Read more
May 11, 2026 Cagrilintide is an experimental long-acting analogue of the human hormone Amylin. Research indicates that Cagrilintide acts as a non-selective agonist of the amylin receptors (AMYR) and the…
Read more
May 11, 2026 CagriSema is a fixed-dose combination research compound consisting of two potent long-acting peptides: Cagrilintide and Semaglutide. Research indicates that CagriSema represents a breakthrough in multi-modal metabolic therapy,…
Read more
Tirzepatide is a novel, synthetic peptide that research indicates is a first-of-its-kind dual agonist, synergistically combining the properties of Glucose-dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) receptor agonists. While…
Read more
May 13, 2026 Dulaglutide is a synthetic fusion protein and long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that research indicates is a powerful modulator of metabolic signaling. Unlike native GLP-1, which…
Read more
May 13, 2026 Glutathione (GSH) is a natural tripeptide composed of the amino acids L-glutamate, L-cysteine, and glycine. Research indicates that it is a potentially fundamental component of the body’s…
Read more